Hope fades: trial of Tay-Sachs drug venglustat terminated early
NCT ID NCT04221451
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This Phase 3 trial tested an oral drug called venglustat in 75 adults and children with late-onset Tay-Sachs or Sandhoff disease, rare genetic disorders that cause progressive nerve damage. The drug aimed to lower toxic fat buildup in the brain and slow disease worsening. However, the study was terminated early, so we don't have clear results on whether it worked.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- venglustat (oral tablet)
- What this could lead to
- If it had succeeded, venglustat could have slowed or stabilized symptoms of Tay-Sachs and Sandhoff diseases by reducing harmful fat buildup in the brain.
- What could go wrong
- The trial was terminated early, so results are limited. It was a small study (75 people) and the drug may not have worked or caused side effects. These are ultra-rare diseases, so findings may not apply broadly.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GM1 GANGLIOSIDOSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
APHP - Centre Hospitalier la Pitié Salpetrière, Service de Neurologie, 47-83 Boulevard De l'Hôpital_Investigational site number 2500001
Paris, 75013, France
-
Ataxia Center and HD Center of Excellence, 300 UCLA Med Plaza, Suite B200 - Investigational site number 8400004
Los Angeles, California, 90095, United States
-
Cambridge University Hospitals NHS Foundation Trust Addenbrookes Hospital Hills Road_investigational site number 8260001
Cambridge, Cambridgeshire, CB2 OQQ, United Kingdom
-
Centro Hospitalar Universitário Lisboa Norte- Hospital Santa Maria Avenida Professor Egas Moniz_investigational site number 6200002
Lisbon, 1649-035, Portugal
-
Clínica Universitaria Reina Fabiola Córdoba_investigational site number 0320001
Córdoba, X5004FHP, Argentina
-
Emory Genetics - Investigational site number 8400006
Atlanta, Georgia, 30322, United States
-
Gazi Universitesi Tip Fakultesi Emniyet Street Mevlana Blv Besevler Yenimahalle_investigational site number 7920001
Ankara, 06500, Turkey (Türkiye)
-
Hospital Clínico Universitario de Santiago-CHUS. Travesia de Chopuana, s/n_investigational site number 7240002
Santiago de Compostela, Galicia [Galicia], 15706, Spain
-
Hospital Maternoinfantil Sant Joan de Déu Paseo de Sant Joan de Déu, 2_investigational site number 7240001
Esplugues de Llobregat, Catalunya [Cataluña], 08950, Spain
-
Hospital Universitari de Bellvitge. Feixa Llarga, S / N_investigational site number 7240004
L'Hospitalet de Llobregat, Barcelona [Barcelona], 08907, Spain
-
Hospital Universitario Austral Pilar, Buenos Aires_Unidad de Investigación Clínica_investigational site number 0320002
Pilar, Buenos Aires, B1629ODT, Argentina
-
Hospital de Clinicas de Porto Alegre _investigational site number 0760001
Porto Alegre, Rio Grande do Sul, 90035 003, Brazil
-
Investigational Site Number : 3800001
Milan, 20133, Italy
-
Investigational Site Number : 8260003
Manchester, M13 9WL, United Kingdom
-
Japanese Red Cross Akita Hospital 222-1 Nawashirosawa, Kamikitatesaruta_investigational site number 3920001
Akita, Akita, 010-1495, Japan
-
Massachusetts General Hospital - Charles River Plaza 175 Cambridge St. Ste 340 - Investigational site number 8400002
Boston, Massachusetts, 02114, United States
-
NIH National Human Genome Research Institute - 10 Center Dr - Bldg. 10 CRC3-2551 MSC 1205 - Investigational site number 8400005
Bethesda, Maryland, 20892, United States
-
NYU Langone - 550 First Avenue-Investigational site number 8400001
New York, New York, 10016, United States
-
Research Center Of Neurology 80, Volokolamskoye shosse_investigational site number 6430001
Moscow, 125367, Russia
-
Salford Royal NHS Foundation Trust Salford Royal Hospital Stott Lane_investigational site number 8260002
Salford, M6 8HD, United Kingdom
-
Tohoku Medical and Pharmaceutical University Hospital_investigation site number 3920002
Sendai, Miyagi, 983-8512, Japan
-
Universitätsklinikum der Justus-Liebig-Universität Gießen Zentrum für Kinderheilkunde und Jugendmedizin Feulgenstraße 10-12_investigational site number 2760001
Giessen, 35390, Germany
-
Vseobecna Fakultni Nemocnice V Praze Metabolicke centrum U Nemocnice 2_investigational site number 2030001
Prague, 12808, Czechia
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a repurposed drug slow rare childhood brain diseases?
- One-Time gene therapy aims to halt rare, fatal brain disease in children
- New pill shows promise for rare brain disorders in early trial
- Small study tracks rare disease to pave way for future treatments
- Scientists track rare brain diseases to pave way for future cures
- Major study tracks rare brain diseases to unlock their secrets